Add Yahoo as a preferred source to see more of our stories on Google. A vial of the Pfizer/BioNTech Comirnaty vaccine against Covid-19 at a mass vaccination center on July 1, 2021 in Leipzig, Germany.

Bayer's Monsanto has sued Pfizer, BioNTech and Moderna for allegedly misusing its messenger RNA technology in COVID vaccines.

A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump ...

Pfizer/BioNTech has initiated its application to the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people ages 16 and older, the companies said Friday. This is the ...

Filed in a Delaware federal court, the lawsuits claim the companies copied technology developed by Bayer's subsidiary, Monsanto, in the 1980s. This pioneering work, originally designed to strengthen ...

Nov 9 (Reuters) - Pfizer Inc (PFE.N), opens new tab said on Monday its experimental vaccine was more than 90% effective in preventing COVID-19 based on initial data from a large study, a major victory ...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...

LP.8.1 variant adapted COVID-19 vaccine COMIRNATY is now authorized in Canada for individuals 6 months of age and older. It is expected to be available in Canada in the coming weeks. This season's ...

(Bloomberg) -- Pfizer Inc. is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech SE, a remnant from one of the pandemic’s most lucrative collaborations. The US drugmaker is ...

BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...

BioNTech (NASDAQ:BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to ...